Investors in Nordics

Siena Secondary Fund provides liquidity for early investors, founders and employees of high growth startups from the Nordics & CEE region. We target companies which are usually post series A, have solid business model and are still in high growth phase.

They are an early-stage investor with a Nordics focus, known for their hands-on approach in supporting high-potential ideas and facilitating entry into global markets. Beyond financial backing, they make a substantial commitment to each portfolio company, leveraging their extensive network and expertise in company-building. Drawing from their collective experience as former technology entrepreneurs who have achieved international success, they empathize with the challenges of scaling businesses and pioneering industry transformation. Alongside their investors, expert network, and founders' collective, they are dedicated to long-term collaboration and support for ambitious ventures.

Linc invests in product oriented companies in the Nordic Life Science industry – primarily in pharmaceutical and medical technology companies. Their investments in drug development usually take place at an early stage, while investments in medical technology are made in more mature businesses.